Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ... benefit managers to pit the products against each other to ...

IQVIA figures on prescriptions for Zepbound and Wegovy, reported by Reuters, suggest that there were nearly 339,000 scrips for Lilly's product in the week ending 18th April, overtaking Novo ...

Zepbound (tirzepatide) is a type of drug called a glucagon-like peptide-1 (GLP-1) receptor agonist. It has the same active ingredient as the type 2 diabetes medication Mounjaro. The Food and Drug ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.